PatientsVille.com Logo

PLEURAL EFFUSION and Prozac

PatientsVille

PLEURAL EFFUSION Symptoms and Causes

Your pleura is a large, thin sheet of tissue that wraps around the outside of your lungs and lines the inside of your chest cavity. Between the layers of the pleura is a very thin space. Normally it's filled with a small amount of fluid. The fluid helps the two layers of the pleura glide smoothly past each other as your lungs breathe air in and out.

Disorders of the pleura include

  • Pleurisy - inflammation of the pleura that causes sharp pain with breathing
  • Pleural effusion - excess fluid in the pleural space
  • Pneumothorax - buildup of air or gas in the pleural space
  • Hemothorax - buildup of blood in the pleural space

Many different conditions can cause pleural problems. Viral infection is the most common cause of pleurisy. The most common cause of pleural effusion is congestive heart failure. Lung diseases, like COPD, tuberculosis, and acute lung injury, cause pneumothorax. Injury to the chest is the most common cause of hemothorax. Treatment focuses on removing fluid, air, or blood from the pleural space, relieving symptoms, and treating the underlying condition.

NIH: National Heart, Lung, and Blood Institute

Check out the latest treatments for PLEURAL EFFUSION

PLEURAL EFFUSION treatment research studies

Prozac clinical trials, surveys and public health registries


Find Drug Side Effect reports



Prozac Side Effects

Depression (189)
Anxiety (147)
Suicidal Ideation (139)
Feeling Abnormal (138)
Suicide Attempt (118)
Nausea (117)
Headache (117)
Completed Suicide (116)
Vomiting (110)
Pain (109)
Insomnia (109)
Aggression (107)
Fall (104)
Dyspnoea (99)
Fatigue (96)
Convulsion (96)
Agitation (95)
Tremor (90)
Abnormal Behaviour (90)
Confusional State (87)
Dizziness (46)
Loss Of Consciousness (45)
Condition Aggravated (45)
Diarrhoea (44)
Asthenia (43)
Somnolence (43)
Overdose (42)
Anger (42)
Homicide (41)
Death (39)
Arthralgia (39)
Malaise (37)
Irritability (35)
Off Label Use (35)
Mania (35)
Weight Decreased (34)
Serotonin Syndrome (34)
Weight Increased (33)
Chest Pain (32)
Hypertension (32)
Crying (32)
Pain In Extremity (31)
Amnesia (31)
Anaemia (29)
Rash (29)
Cerebrovascular Accident (29)
Syncope (27)
Hyperhidrosis (26)
Pruritus (26)
Hyponatraemia (26)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

At one time I was on the lowest dose possible and had no side effects at all, I should of continued the medication, I now am trying prstiq and that knocked me out. Don't know what to do now.

Can prozac cause hallucinations?

Does 10mg of prozac cause pesonality changes?

Does anyone know if prozac would give me more energy, every antidepressant I have tried just knocks me out to the point I can not function they all seem to make make me so tired. please help thank you Brenda I have sever anxiety attacks can not sleep

Unresponsive to 5mg/kg q 8wks; increased to 10mg/kg q6wks. After 3 doses at that strength noted fatigue, occasional night sweats, joint aches, sudden onset of chest pain and dyspnea (pleurisy, small pleuraleffusion) Had just taper

54y/o, WM, Status post quadruple coronary artery bypass graft surgery(10 months ago). Surgery went well, only complication was a pretty large left pleural effusion requiring chest tube placement. Resolved well, no further problems

Experienced weakness and fatigue, diagnosed with pericardial effusion and anemia, hospitalized for 14 days. Surgical thorectomy and drainage.

Feb 2009 hospitalized for pericardal effusion then suffered with reaccuring pericarditis for a year march 2101 sent to mayo clinic in minnasota for a radical pericardectomy

Hi am a nursing student and my pt has pneumonia and pleural effusion and empyema withlarge abcessand the hostpital is giving him perfalgan is that wrong?

My father died last week after suffering from: fluid buildup in the lining of the lungs (pleural effusion), heart (pericardial effusion), led to hard breathing, fatigueandvery low oxygen in

When people receive a lung transplant, the pleural cavity is destroyed. How are people able to breathe following a lung transplant when there is no pleural cavity???

PLEURAL EFFUSION Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Not yet recruiting Fluoxetine Prevention Trial
Condition: Cognitive Dysfunction
Interventions: Drug: Fluoxetine;   Drug: Placebo
Outcome Measures: Change from baseline in regional cerebral metabolism;   Durability of the protective effect of fluoxetine;   Change from baseline in neuropsychological (cognitive, functional) test results;   Correlation between cognitive functioning and cerebral metabolism by correlating neuropsychological testing results with PET imaging;   Correlation between inflammatory cytokines and cerebral metabolism by correlating blood cytokine marker levels with PET imaging
2 Not yet recruiting "Evaluation by Transcranial Magnetic Stimulation of the Benefit of Fluoxetine on Motor Recovery After Stroke"
Condition: Cerebral Infarction
Interventions: Drug: Fluoxetine;   Drug: Placebo of fluoxetine
Outcome Measures: Slope of the curve of recruitment of the PEMs;   Slope of recruitment of the PEMs;   Index finger force control in paretic hand under time-course of treatment of Fluoxetine;   in index finger force control in non-paretic hand under time-course of treatment of Fluoxetine
3 Unknown  Predictors of Treatment Response to Fluoxetine in PTSD Following a Recent History of War Zone Stress Exposure
Condition: Posttraumatic Stress Disorder, Combat-related
Interventions: Drug: Fluoxetine;   Drug: Placebo
Outcome Measures: Clinician Administered PTSD Scale;   PTSD Symptom Checklist
4 Recruiting A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression
Condition: Treatment Resistant Depression
Interventions: Drug: Olanzapine;   Drug: Fluoxetine;   Drug: Placebo
Outcome Measures: Mean Change from Baseline to 8 Week Endpoint in Montgomery-Äsberg Depression Rating Scale (MADRS);   Mean Change from Baseline to 8 Week Endpoint in Clinical Global Impressions-Severity of Depression (CGI-S) Scale;   Mean Change from Baseline to 8 Week Endpoint in the Simpson-Angus Scale (SAS);   Mean Change from Baseline to 8 Week Endpoint in the Short-Form 36 Health Survey (SF-36);   Mean Change from Baseline to 8 Week Endpoint in the Sheehan Disability Scale (SDS);   Percentage of Participants who Achieve a Response Based on a ≥50% Reduction from Baseline in MADRS Total Score;   Percentage of Participants who Achieve Remission Based on MADRS Total Score ≤10 at 8 Weeks;   Mean Change from Baseline to 8 Week Endpoint in the Barnes Akathisia Scale (BAS);   Mean Change from Baseline to 8 Week Endpoint in the Abnormal Involuntary Movement Scale (AIMS)
5 Recruiting Role of Inflammation Factors and Insulin Resistance in Major Depressive Disorder
Condition: Major Depressive Disorder
Interventions: Drug: Fluoxetine + Valsartan;   Drug: Fluoxetine + Placebo
Outcome Measures: Hamilton Depression Rating Scale (HDRS);   fasting plasma glucose;   fasting serum insulin;   C-reactive Protein, and IL-6
6 Recruiting Effectiveness Study to Compare Venlafaxine With Fluoxetine in the Treatment of Postmenopausal Women With Major Depression
Condition: Major Depression
Intervention: Drug: venlafaxine,fluoxetine
Outcome Measures: change of 24-item Hamilton Rating Scale for Depression total score;   the mean change of HAMD-24 subscale score in items 10, 11, 12, 13 (anxiety and somatizations) at endpoint
7 Recruiting Fluoxetine for Motor, Aphasia, and Neglect Recovery After Ischemic Stroke
Condition: Stroke
Interventions: Drug: fluoxetine;   Drug: placebo
Outcome Measures: Fugl-Meyer Motor Scale (FMMS);   Western Aphasia Battery;   Behavioral Inattention Test (BIT);   Functional Independence Measure
8 Recruiting Fluoxetine for Motor Recovery After Acute Intracerebral Hemorrhage
Conditions: Intracerebral Hemorrhage;   Motor Impairment
Interventions: Drug: Fluoxetine;   Drug: Placebo
Outcome Measures: Fugl Meyer Motor Scale score;   Barthel Index;   modified Rankin Scale;   NIH Stroke Scale
9 Unknown  Safety and Efficacy of Fluoxetine in Pulmonary Arterial Hypertension
Condition: Pulmonary Arterial Hypertension
Intervention: Drug: Fluoxetine
Outcome Measures: The primary endpoint will be change in pulmonary vascular resistance (PVR) measured by right heart catheterization after three months of therapy.;   Efficacy, Safety and tolerability endpoints will include change between baseline and three month QIDS-SR depression scale, systolic and diastolic blood pressure (systemic) and tabulation of adverse events
10 Recruiting Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus (DM)
Conditions: Type 1 Diabetes;   Hypoglycemia Associated Autonomic Failure
Interventions: Drug: Fluoxetine;   Drug: Placebo control
Outcome Measure: Change in Catecholamines
11 Unknown  Pharmacogenomics Studies of Antidepressants
Conditions: Major Depressive Disorder;   Antidepressive Agents;   Pharmacogenetics;   Venlafaxine;   Fluoxetine
Interventions: Drug: Venlafaxine;   Drug: Fluoxetine
Outcome Measures: Hamilton Depression Rating Scale (HDRS);   C-reactive Protein and IL-6;   fasting blood glucose, lipid profiles
12 Recruiting Developing Adaptive Treatment Strategies for Children and Adolescents With Obsessive-compulsive Disorder.
Condition: Obsessive-Compulsive Disorder
Interventions: Drug: fluoxetine;   Behavioral: Group cognitive-behavioral therapy
Outcome Measures: Treatment response status at week 28;   Treatment response status at week 14;   Predictors of treatment response at week 28
13 Not yet recruiting RCT of a Neuroplasticity Agent and CI Therapy for Severe Arm Paresis After Stroke
Condition: Severe Stroke With Affected Arm Motor Function
Interventions: Drug: Fluoxetine;   Drug: Placebo;   Procedure: eCMIT;   Procedure: Usual Care
Outcome Measures: Grade 4/5 Motor Activity Log (MAL) Arm Use Scale;   Grade 4/5 MAL Arm Use scale;   Grade 4/5 Wolf Motor Function Test Performance Rate score
14 Recruiting A Positron Emission Topographic (PET) Study on Depression Patient With Electroacupuncture
Conditions: Major Depressive Disorder;   Depression
Interventions: Drug: Fluoxetine;   Procedure: DCEAS (Hwato®/ Dongbang®);   Procedure: n-CEA (Strietberger®)
Outcome Measures: HAMD-17;   SDS;   PET scanning;   Clinical response;   Remission;   Latency;   Adverse events
15 Recruiting Characterization and Sequential Pharmacotherapy of Severe Mood Dysregulation
Condition: Severe Mood Dysregulation
Interventions: Drug: lisdexamfetamine;   Drug: Placebo;   Drug: fluoxetine
Outcome Measures: Clinical Global Impression-Improvement-Severe Mood Dysregulation;   Pediatric Anxiety Rating Scale (PARS);   Children's Depression Rating Scale;   ADHD-IV Rating Scale;   ADHD IV Rating Scale;   Columbia Suicide Severity Scales;   Barnes Akathisia Scale;   Children's Affective Lability Scale;   Physical Symptom Checklist;   Revised Modified Overt Aggression Scale;   Screen for Children's Affective Reactivity;   Affective Reactivity Index
16 Recruiting Efficacy of Exposure and Response Prevention(ERP) and SSRIs in Chinese OCD Patients
Conditions: Obsessive-Compulsive Disorder;   Anxiety Disorders;   Mental Disorders
Interventions: Drug: Fluoxetine;   Drug: Sertraline;   Drug: Paroxetine;   Drug: Citalopram;   Drug: Fluvoxamine;   Behavioral: Exposure and Response Prevention
Outcome Measures: The change of Yale-Brown Obsessive-Compulsive Scale score;   The change of Beck Depression Inventory(BDI-II) score;   The change of Beck Anxiety Inventory(BAI) score;   The change of Stress Perceived Questionnaire (PSS-10) score;   The change of Behavioral Inhibition/Behavioral Activation System Scales score;   The change of Barratt Impulsiveness Scale 11 (BIS-11) score;   The change of Obsessive Beliefs Questionnaire-44(OBQ-44) score;   The NEO-Five Factor Inventory-Revised (NEO-FFI-R);   The Early Trauma Inventory Self Report-Short Form(ETISR-SF)
17 Recruiting Clinical Trial of Fluoxetine in Anxiety and Depression in Children, and Associated Brain Changes
Conditions: Depression;   Mood Disorder;   Anxiety Disorder;   Healthy
Intervention:
Outcome Measure:
18 Recruiting Comparing Treatments for Self-Injury and Suicidal Behavior in People With Borderline Personality Disorder
Conditions: Borderline Personality Disorder;   Suicide
Interventions: Drug: Fluoxetine;   Behavioral: DBT;   Drug: Citalopram
Outcome Measure: Suicidal and self-injurious behavior
19 Recruiting An Adaptive Treatment Strategy for Adolescent Depression-Continuation
Condition: Adolescent Depression
Interventions: Drug: Fluoxetine;   Behavioral: Interpersonal Psychotherapy
Outcome Measures: K-SADS-PL - baseline; change from baseline in KSADS at week 16 and 32;   BDI-II-baseline; change from baseline in BDI at weeks 4/8/12/16/24/32;   HRSD-baseline; change from baseline in HRSD at weeks 4/8/12/16/24/32;   CSSR-S-baseline; change from baseline in CSSR-S at weeks 4/8/12/16/24/32
20 Recruiting An Adaptive Treatment Strategy for Adolescent Depression
Condition: Adolescent Depression
Interventions: Drug: Fluoxetine;   Behavioral: Interpersonal Psychotherapy
Outcome Measures: K-SADS-PL - baseline; change from baseline in KSADS at week 16 and 32;   BDI-II-baseline; change from baseline in BDI at weeks 4/8/12/16/32;   HRSD-baseline; change from baseline in HRSD at weeks 4/8/12/16/32;   CSSR-S-baseline; change from baseline in CSSR-S at weeks 4/8/12/16/32